Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Antidepressant Drugs: Overview

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Risperidone-induced priapism in a middle-aged adult: Preventive considerations.

Asian journal of psychiatry·2025

Same author

Symptom Severity and Sociodemographic Correlates of the Suicide Crisis Syndrome in Major Depression: A Multicentric Investigation.

Archives of suicide research : official journal of the International Academy for Suicide Research·2025

Same author

Factor structure, reliability, and validity of the revised Suicide Crisis Inventory in major depression: A multicentric Indian study.

Journal of affective disorders·2023

Same author

Morvan's syndrome Presenting with Psychiatric Manifestations - A Case Report and Review of the Literature.

Neurology India·2022

Same author

A randomized, double-blind, placebo-controlled, 12-week trial of vitamin D augmentation in major depressive disorder associated with vitamin D deficiency.

Journal of affective disorders·2022

Same author

Clozapine-Associated Myopathic Dysfunction.

American journal of therapeutics·2022

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

The Forced Swim Test as a Model of Depressive-like Behavior

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

Fluoxetine induced extrapyramidal symptoms : case reports.

S H Nizamie¹, P N Suresh Kumar

¹S. HAQUE NIZAMIE, M.D., D.P.M., Professor of Psychiatry, Central Institute of Psychiatry, Ranchi -834006.

Indian Journal of Psychiatry

|April 16, 2011

Summary

Fluoxetine can rarely cause extrapyramidal symptoms, such as movement disorders. This may occur due to serotonin affecting dopamine pathways in the brain.

Keywords:

Fluoxetine extrapyramidal symptoms

More Related Videos

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

Related Experiment Videos

Last Updated: Jun 2, 2026

The Forced Swim Test as a Model of Depressive-like Behavior

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

Area of Science:

Neuroscience
Pharmacology
Clinical Medicine

Background:

Fluoxetine is a widely prescribed selective serotonin reuptake inhibitor (SSRI).
Extrapyramidal symptoms (EPS) are movement disorders typically associated with dopamine pathway dysfunction.
While SSRIs are generally not associated with EPS, rare cases have been reported.

Purpose of the Study:

To report a rare case of extrapyramidal symptoms induced by fluoxetine.
To explore the potential mechanism underlying fluoxetine-induced EPS.

Main Methods:

This is a case report detailing a patient's experience with fluoxetine.
Clinical observations and pharmacological principles were used to analyze the event.

Main Results:

The patient developed extrapyramidal symptoms after initiating fluoxetine treatment.
A proposed mechanism involves serotonin's influence on dopamine blockade at the nigrostriatal level.

Conclusions:

Fluoxetine can, in rare instances, induce extrapyramidal symptoms.
Serotonin-mediated dopamine blockade is a plausible mechanism for this adverse effect.